Researchers from Centre National de la Recherche Scientifique, Inserm, Université Claude Bernard and Université Jean Monnet have synthesized peptides acting as amyloid-β (Aβ) protein aggregation inhibitors reported to be useful for the treatment of amyotrophic lateral sclerosis, cerebral amyloid angiopathy, Down syndrome, Parkinson's disease, Alzheimer's disease and motor neuron disease.

Korea Research Institute of Chemical Technology has disclosed mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) and mitogen-activated protein kinase kinase kinase 11 (MAP3K11; MLK3) inhibitors reported to be useful for the treatment of Parkinson's disease, viral infection, cancer, tuberculosis and non-alcoholic steatohepatitis.

Esperion Therapeutics Inc. has described ATP citrate lyase (ACLY) inhibitors reported to be useful for the treatment of cancer and more.

Novartis AG has divulged pyrazolopyrimidine derivatives acting as methylcytosine dioxygenase TET2 inhibitors and thus reported to be useful for the treatment of cancer.

Merck Sharp & Dohme LLC has identified orexin OX2 receptor agonists reported to be useful for the treatment of hypersomnia and narcolepsy.

Aria Pharmaceuticals Inc. has synthesized compounds acting as caspase-1 (IL-1β-converting enzyme) and pyroptosis inhibitors reported to be useful for the treatment of alopecia, autoimmune hemolytic anemia, chronic kidney disease, duodenal ulcer, hepatitis B, osteoarthritis, systemic lupus erythematosus and uveitis, among others.

West China Hospital of Sichuan University has disclosed piperidine derivatives acting as μ-opioid receptor agonists and sigma non-opioid intracellular receptor 1 (SIGMAR1) antagonists.

Treeline Biosciences Inc. has described proteolysis targeting chimeras (PROTACs) comprising cereblon (CRBN) ligands coupled to a Bcl-2-like protein 1 (Bcl-xL; Bcl-X; BCL2L1) targeting moiety via linker acting as Bcl-xL degradation inducers.

Revolution Medicines Inc. has divulged son of sevenless homolog 1 (SOS1) inhibitors reported to be useful for the treatment of cancer, neurofibromatosis type 1, cardiofaciocutaneous, Noonan, Costello and Legius syndrome (neurofibromatosis type 1-like syndrome), among others.

Yale University has identified compounds reported to be useful for the treatment of dry age-related macular degeneration (AMD), Fuchs endothelial corneal dystrophy, cataract, glaucoma and keratoconus.